Is Sandu Pharma. overvalued or undervalued?

As of 22 September 2025, Sandu Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 29.31, an EV to EBITDA of 15.84, and a Price to Book Value of 1.09.
In comparison to its peers, Sandu Pharma's PE Ratio is significantly lower than Elitecon International, which is deemed very expensive at 447.83, and also lower than MMTC, which has a PE of 150.41. However, it is worth noting that PTC India, which is classified as very attractive, has a much lower PE Ratio of 8.31, highlighting that Sandu Pharma may still have room for improvement in its valuation. Recent stock performance shows that Sandu Pharma has underperformed against the Sensex, particularly over the past year with a decline of 24.87% compared to a slight drop of 2.82% in the Sensex, reinforcing the notion that the stock may be fairly valued at this time.